Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a ...

Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half ...

The European stock markets were mixed, though relatively flat in Monday trading as The Stoxx Europe 600 was off 0.04%, Germany's DAX dipped 0.01%, the FTSE 100 in London gained 0.04%, France's CAC 40 ...

Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular ...

Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their ...

In 2023, the United States marked a major milestone in the battle against a longstanding public health crisis: adult obesity rates dropped for the first time in a decade. Researchers pointed to GLP-1s ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Sligo recorded the highest commercial vacancy rate at 20.6 per cent, followed closely by Donegal at 20.1 per cent and Galway ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Pharmaceutical giants are squaring off against telehealth companies and pharmacies selling custom-made versions of the hot ...